Avidity Biosciences PE Ratio 2019-2022 | RNA
Current and historical p/e ratio for Avidity Biosciences (RNA) from 2019 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Avidity Biosciences PE ratio as of May 20, 2022 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Avidity Biosciences PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2022-05-23 |
13.24 |
|
0.00 |
| 2022-03-31 |
18.47 |
$-2.91 |
0.00 |
| 2021-12-31 |
23.77 |
$-2.84 |
0.00 |
| 2021-09-30 |
24.63 |
$-2.45 |
0.00 |
| 2021-06-30 |
24.71 |
$-2.08 |
0.00 |
| 2021-03-31 |
21.81 |
$-2.61 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.644B |
$0.009B |
|
Avidity Biosciences Inc. is a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates(TM). The company's AOC platform design, engineer and develop therapeutics which combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies. Its lead product candidate consist AOC 1001, is designed to treat myotonic dystrophy type 1,and other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. Avidity Biosciences Inc. is based in SAN DIEGO.
|
